Monday, December 26, 2011

Royal Jelly Anti-Tumor Effect Studied

Royal Jelly posseses very important components. One in particular, the amazing 10H2DA, is currently being studied to stop cancer cells from growing, modulate Estrogen and treat Rheumatoid Arthritis (RA). The natural wonders of the beehive, known as Apitherapy, have real therapeutic value.

Inhibition of Interferon-γ-Induced Nitric Oxide Production by 10-Hydroxy-Trans-2-Decenoic Acid Through Inhibition of Interferon Regulatory Factor-8 Induction

10-Hydroxy-trans-2-decenoic acid (10H2DA) is a major lipid component of royal jelly, a honey bee secretion used to nourish the queen bee and young larvae.

In this study, we examined the effect of 10H2DA on interferon (IFN)-γ-induced nitric oxide (NO) production. IFN-γ-induced NO production and activation of the inducible NO synthase promoter were significantly inhibited by 10H2DA. IFN-γ-induced phosphorylation of signal transducer and activator of transcription-1 was not affected by 10H2DA. In contrast, IFN-γ-induced tumor necrosis factor (TNF)-α production and nuclear factor (NF)-κB activation were inhibited by 10H2DA. IFN-γ-mediated induction of interferon regulatory factor (IRF)-8, but not IRF-1, was also inhibited by 10H2DA. IFN-γ-induced TNF-α production followed by activation of NF-κB is known to be essential for NO production.

Together, 10H2DA inhibited IFN-γ-induced NO production by inhibiting IRF-8 induction and TNF-α production. 10H2DA might modulate IFN-γ-mediated cellular responses by inhibiting the induction of IRF-8 and IRF-8-dependent genes.

No comments:

Post a Comment